Corcept Therapeutics (CORT) Receivables - Other (2019 - 2026)

Corcept Therapeutics has reported Receivables - Other for 8 years, with the latest figure at $4.5 million in Q2 2026.

• Quarterly Receivables - Other rose 9.76% year-over-year to $4.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.5 million (up 9.76% YoY) and the FY2025 annual result came in at $4.1 million, up 129.29% from the prior year.
• Receivables - Other advanced to $4.5 million in Q2 2026 per CORT's latest filing, from $3.9 million in the prior quarter.
• Over five years, Receivables - Other peaked at $18.2 million in Q1 2025 and troughed at -$14.0 million in Q1 2024.
• A 5-year average of $5.8 million and a median of $4.0 million in 2025 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 1455.56% in 2023, then plunged 200.0% in 2024.
• Over 5 years, Receivables - Other stood at $14.0 million in 2022, then changed by 0.0% to $14.0 million in 2023, then sank by 79.29% to $2.9 million in 2024, then soared by 34.48% to $3.9 million in 2025, then rose by 15.38% to $4.5 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $4.5 million, $3.9 million, and $4.1 million for Q2 2026, Q3 2025, and Q2 2025 respectively.